Compare Southwest Airlines Co (LUV) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Repligen Corporation Common Stock — how do they compare? Southwest Airlines Co trades at $39.3 (market cap $19.89B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.77% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 66 Days and Repligen Corporation Common Stock for 0 Days on average.
| LUV | RGEN | |
|---|---|---|
Market Cap | $19.89B | $11.14B |
Volume | 3,985,163 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $54.80 | $194.57 |
52-Week Low | $29.67 | $102.87 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $22.98B | $11.02B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $39.34, down 3.48% today, showing bearish technical signals with mixed earnings performance. The company reported a Q2 2026 EPS beat ($0.94 vs $0.51 expected) but missed Q1 expectations. Fundamentals show modest revenue growth to $28.06B in 2025 with a thin 2.78% net margin, though valuation appears reasonable with P/S of 0.71 and P/E of 25.41. Recent news highlights Southwest's commercial transformation initiatives targeting over $2B EBIT in 2026.
LUV presents a turnaround opportunity with analyst consensus target of $49.61 offering 26% upside, though near-term headwinds from high fuel costs and competitive pressures persist. The stock's bearish technical setup and volatile earnings history require careful risk management, but successful execution of revenue initiatives could drive significant shareholder value.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
